Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer

References

• Zhang Y, Frampton AE, Kyriakides C, et al. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2012;138(6):1063–1071. doi:10.1007/s00432-012-1165-722392075
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Morton CA, Al-Saadi S, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg. 2010;76(5):480–485.20506876
   PubMed Web of Science ®Google Scholar
• Van Den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35(6):600–604. doi:10.1016/j.ejso.2008.12.00619131205
   PubMed Web of Science ®Google Scholar
• Zhou Y, Song A, Wu L, Si X, Li Y. Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: a pooled analysis. Pancreatology. 2016;16(6):1124–1128. doi:10.1016/j.pan.2016.09.01527717684
   PubMed Web of Science ®Google Scholar
• Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20(3):964–972. doi:10.1245/s10434-012-2762-z23233235
   PubMed Web of Science ®Google Scholar
• Thomas RM, Truty MJ, Nogueras-Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16(9):1696–1704. doi:10.1007/s11605-012-1912-822644446
   PubMed Web of Science ®Google Scholar
• Halperin EC, Wazer DE, Perez CA, Brady LW. Perez & Brady’s Principles and Practice of Radiation Oncology, Seventh Edition. Lippincott Williams & Wilkins (LWW); 2018. Philadelphia.
   Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi:10.1200/JCO.1995.13.1.87799047
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–382. doi:10.1038/nrclinonc.2011.4421423255
   PubMed Web of Science ®Google Scholar
• Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107–111. doi:10.1093/jjco/hyp16720047860
   PubMed Web of Science ®Google Scholar
• Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP. 2006;7(1):34–40.16407616
   PubMedGoogle Scholar
• Habermehl D, Brecht IC, Bergmann F, et al. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiat Oncol. 2013;8:27. doi:10.1186/1748-717X-8-2723369246
   PubMed Web of Science ®Google Scholar
• Nakamura A, Itasaka S, Takaori K, et al. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis. Strahlenther Onkol. 2014;190(5):485–490. doi:10.1007/s00066-014-0610-824599344
   PubMed Web of Science ®Google Scholar
• Comito T, Cozzi L, Zerbi A, et al. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: a retrospective study. Eur J Surg Oncol. 2017;43(4):735–742. doi:10.1016/j.ejso.2016.12.01228131670
   PubMed Web of Science ®Google Scholar
• Sutera P, Bernard ME, Wang H, et al. Stereotactic body radiation therapy for locally progressive and recurrent pancreatic cancer after prior radiation. Front Oncol. 2018;8:52. doi:10.3389/fonc.2018.0005229564223
   PubMed Web of Science ®Google Scholar
• Dagoglu N, Callery M, Moser J, et al. Stereotactic Body Radiotherapy (SBRT) reirradiation for recurrent pancreas cancer. J Cancer. 2016;7(3):283–288. doi:10.7150/jca.1329526918041
   PubMed Web of Science ®Google Scholar
• Koong AJ, Toesca DAS, von Eyben R, Pollom EL, Chang DT. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Adv Radiat Oncol. 2017;2(1):27–36. doi:10.1016/j.adro.2017.01.00328740913
   PubMedGoogle Scholar
• Watanabe H, Okada M, Kaji Y, et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. Gan to Kagaku Ryoho Cancer Chemother. 2009;36(13):2495–2501.
   PubMedGoogle Scholar
• Winter JM, Tang LH, Klimstra DS, et al. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg. 2013;258(2):331–335. doi:10.1097/SLA.0b013e31827fe9ce23360922
   PubMed Web of Science ®Google Scholar
• Oshima M, Okano K, Muraki S, et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013;258(2):336–346. doi:10.1097/SLA.0b013e3182827a6523470568
   PubMed Web of Science ®Google Scholar
• Herman JM, Fan KY, Wild AT, et al. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2013;87(3):458–459. doi:10.1016/j.ijrobp.2013.06.203924074918
   PubMed Web of Science ®Google Scholar
• Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29(22):3037–3043. doi:10.1200/JCO.2010.33.803821709185
   PubMed Web of Science ®Google Scholar
• Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22(2):670–676. doi:10.1245/s10434-014-4021-y25155401
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ueno H, Ikeda M, et al. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology. 2009;77(3–4):217–223. doi:10.1159/00023602219729980
   PubMed Web of Science ®Google Scholar
• Chari ST, Kelly K, Hollingsworth MA, et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas. 2015;44(5):693–712. doi:10.1097/MPA.000000000000036825931254
   PubMed Web of Science ®Google Scholar
• Ouyang H, Ma W, Zhang T, et al. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. Pancreatology. 2018;18(8):983–989. doi:10.1016/j.pan.2018.09.01530287168
   PubMed Web of Science ®Google Scholar
• Hong Y, Rice J, Sharma D, Martin RCG 2nd. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer. Am J Surg. 2018;216(1):106–110. doi:10.1016/j.amjsurg.2018.01.03729506753
   PubMed Web of Science ®Google Scholar
• Hua YQ, Wang P, Zhu XY, et al. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: an analysis of safety and efficacy. Pancreatology. 2017;17(6):967–973. doi:10.1016/j.pan.2017.08.07229129384
   PubMed Web of Science ®Google Scholar
• F PK L, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27(4):358–367. doi:10.3978/j.issn.1000-9604.2015.05.0226361405
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–1117. doi:10.1038/nature0951520981102
   PubMed Web of Science ®Google Scholar
• Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378–382. doi:10.1038/nature1982327732578
   PubMed Web of Science ®Google Scholar
• Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S101–S107. doi:10.1016/j.ijrobp.2009.05.07120171503
   PubMed Web of Science ®Google Scholar
• Krempien R, Roeder F. Intraoperative radiation therapy (IORT) in pancreatic cancer. Radiat Oncol. 2017;12(1):8. doi:10.1186/s13014-016-0753-028069018
   PubMed Web of Science ®Google Scholar
• Fernandez-Cruz L, Johnson C, Dervenis C. Locoregional dissemination and extended lymphadenectomy in pancreatic cancer. Dig Surg. 1999;16(4):313–319. doi:10.1159/00001874110449976
   PubMed Web of Science ®Google Scholar
• Ozaki H, Hiraoka T, Mizumoto R, et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today. 1999;29(1):16–22. doi:10.1007/BF024829649934826
   PubMed Web of Science ®Google Scholar
• Cheng H, Luo G, Lu Y, et al. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 2016;16(6):1080–1084. doi:10.1016/j.pan.2016.09.00727665172
   PubMed Web of Science ®Google Scholar
• Guo M, Luo G, Liu C, et al. The prognostic and predictive role of epidermal growth factor receptor in surgical resected pancreatic cancer. Int J Mol Sci. 2016;17(7):1090. doi:10.3390/ijms17071090
   PubMed Web of Science ®Google Scholar